TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25130401

Group type: EXPERIMENTAL
Intervention: Lumiliximab in combination with fludarabine, cyclophosphamide and rituximab (FCR)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide and rituximab (FCR) alone
Number of subjects: 627
Study: 22533481

Group type: EXPERIMENTAL
Intervention: Dietitian-coached group (DC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 101
Study: 19557400

Group type: EXPERIMENTAL
Intervention: Improved quality of discharge summary with clinical pharmacists reviewing and providing feedback on the medication report before discharge.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with standard discharge summary process.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Intervention group with improved discharge summary process.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Patients using the ApoDos medication dispensing system.
Number of subjects: 115
Study: 17720113

Group type: COMPARATOR
Intervention: Through-the-needle (TTN) injection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Through-the-catheter (TTC) anesthesia
Number of subjects: 80
Study: 16344052

Group type: EXPERIMENTAL
Intervention: Computer-aided polyp detection (CAD) program
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Optical colonoscopy
Number of subjects: 1186
Study: 12269719

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) with electrical stimulation at 4 pulses/second for 20 minutes, 6 treatments over 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual acupuncture (MA) with needle retained for 20 minutes after Deqi sensation, 6 treatments over 2 weeks
Number of subjects: 20
Study: 10204815

Group type: EXPERIMENTAL
Intervention: beta-blockade (atenolol, metoprolol, pindolol, propranolol)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 35
Study: 7554521

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) 5 mg/kg/day and prednisolone 10 mg/day for up to 8 months
Number of subjects: 30
Study: 2405113

Group type: EXPERIMENTAL
Intervention: Mailed self-care pamphlet for URI care
Number of subjects: 20127

Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 20127

Group type: COMPARATOR
Intervention: All patients (experimental and control)
Number of subjects: 20127
Study: 7025715

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 8
Study: 28862032

Group type: EXPERIMENTAL
Intervention: Heparin pre-treatment
Number of subjects: 7144

Group type: COMPARATOR
Intervention: Control group (no heparin pre-treatment)
Number of subjects: 7144
Study: 28160513

Group type: EXPERIMENTAL
Intervention: Pru p 3 sublingual immunotherapy (SLIT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 48
Study: 26586494

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fatigue education and support (ES)
Number of subjects: 71
Study: 25516024

Group type: EXPERIMENTAL
Intervention: Depression intervention (up to 10 one-hour sessions over 4 months)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Depression intervention
Number of subjects: 208
Study: 22959984

Group type: EXPERIMENTAL
Intervention: OPV0
Number of subjects: 342

Group type: COMPARATOR
Intervention: No OPV0
Number of subjects: 342

Group type: COMPARATOR
Intervention: No OPV0 (boys)
Number of subjects: 342
Study: 19293594

Group type: EXPERIMENTAL
Intervention: Physical activity (measured as steps/day) in HD patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Physical activity (measured as steps/day) in PD patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Highest category of steps/day in HD patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Physical activity in PD patients
Number of subjects: 61
Study: 17853636

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (MBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 15266338

Group type: EXPERIMENTAL
Intervention: Single agent carboplatin
Number of subjects: 361

Group type: COMPARATOR
Intervention: Cisplatin-based combinations
Number of subjects: 361
Study: 11372583

Group type: EXPERIMENTAL
Intervention: Intracutaneous indomethacin (10 micrograms/ml and 100 micrograms/ml)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peroral indomethacin (100 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mepyramine (10 micrograms/ml)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intracutaneous NDGA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peroral zafirlukast (40 mg)
Number of subjects: 51
Study: 9844453

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Metronidazole (500 mg/12 h)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Amoxicillin (1 g/12 h)
Number of subjects: 48
Study: 7862925

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.4 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 2510267

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.d.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Rioprostil and Ranitidine
Number of subjects: 156
Study: 1099445

Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31242892

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (12 sessions of 90 min, once a week led by two Primary Care nurses)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 504
Study: 28582808

Group type: EXPERIMENTAL
Intervention: A. muricata leaf extract
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25925487

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention protocol for pelvic floor muscle training (30 min, twice a week, total of 10 sessions)
Number of subjects: 46
Study: 24033725

Group type: EXPERIMENTAL
Intervention: Flow-driven (FD) device (RM3; Waters Medical Inc)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pressure-driven (PD) device (LifePort; Organ Recovery Systems)
Number of subjects: 50
Study: 22204203

Group type: EXPERIMENTAL
Intervention: Transpatellar approach (t-group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medial parapatellar approach (p-group)
Number of subjects: 50
Study: 18281440

Group type: EXPERIMENTAL
Intervention: Persistently Violent Offender program
Number of subjects: 256

Group type: COMPARATOR
Intervention: Alternate program
Number of subjects: 256

Group type: COMPARATOR
Intervention: Program noncompletion
Number of subjects: 256
Study: 16681477

Group type: EXPERIMENTAL
Intervention: 20-mg tadalafil taken on demand
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: 20-mg tadalafil taken three times per week
Number of subjects: 4262
Study: 14769687

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 11742886

Group type: EXPERIMENTAL
Intervention: Whole-grain meal daily for 16 weeks
Number of subjects: 76
Study: 9236562

Group type: EXPERIMENTAL
Intervention: Nizatidine 225 mg
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Nizatidine 25 mg
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 7599447

Group type: EXPERIMENTAL
Intervention: Combined sodium monofluorophosphate and calcium therapy (FC) - 13.2 mg F- (100 mg sodium monofluorophosphate) and 500 mg Ca2+, administered twice a day for 2 years
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (C) - 500 mg Ca2+, administered twice a day for 2 years
Number of subjects: 94
Study: 2095973

Group type: EXPERIMENTAL
Intervention: Gallopamil (0.03 mg/kg iv)
Number of subjects: 12
Study: 488880

Group type: EXPERIMENTAL
Intervention: 4.0 g Paromomycin administered on each of the two preoperative days combined with mechanical cleansing of the intestine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (Not-Humatin group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Overall group (both intervention and control)
Number of subjects: 156
Study: 31151458

Group type: EXPERIMENTAL
Intervention: E-RS:COPD
Number of subjects: 338
Study: 28271427

Group type: EXPERIMENTAL
Intervention: WebMOVE (computerized weight management with peer coaching)
Number of subjects: 276

Group type: COMPARATOR
Intervention: In-person clinician-led weight services
Number of subjects: 276

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study: 25864906

Group type: EXPERIMENTAL
Intervention: Spiritual Meditation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Internally Focused Secular Meditation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Externally Focused Secular Meditation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation
Number of subjects: 92
Study: 23709409

Group type: EXPERIMENTAL
Intervention: Brain-directed nutrients (BDNs) including fish oil, a high-potency multiple vitamin/mineral supplement, and a brain-enhancement supplement.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brain-directed nutrients (BDNs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21216328

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (3 ml via hand-held inhaler)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline scented to maintain blindness, 3 ml via hand-held inhaler)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19638968

Group type: EXPERIMENTAL
Intervention: Warm water consumption (2 l) before colonoscopy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Cold water consumption (2 l) before colonoscopy
Number of subjects: 192

Group type: COMPARATOR
Intervention: No water consumption before colonoscopy
Number of subjects: 192
Study: 17312064

Group type: EXPERIMENTAL
Intervention: Group 1 (5, 20, 45 seconds)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Group 2 (10, 25, 50 seconds)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Group 3 (15, 30, 55 seconds)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Group 1, Group 2, Group 3
Number of subjects: 170
Study: 15527500

Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Having pets at home
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Exposure to nitrogen dioxide (NO2)
Number of subjects: 996
Study: 19667564

Group type: EXPERIMENTAL
Intervention: Sibutramine with individualized weight-management program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher level of physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New management system
Number of subjects: 0
Study: 8638298

Group type: EXPERIMENTAL
Intervention: Total stripping of the long saphenous vein (n = 84)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Partial stripping of the long saphenous vein (n = 79)
Number of subjects: 163
Study: 2057468

Group type: EXPERIMENTAL
Intervention: Intervention group (family intervention with advice on diet, smoking, and exercise)
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: Intervention group (family intervention)
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: Children in intervention group
Number of subjects: 1373
Study: 6315789

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Griseofulvin ultramicrosize
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical antifungal cream (after clinical cure)
Number of subjects: 16
Study: 29357757

Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with cognitive behavioral therapy (MI‐CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 10
Study: 29724385

Group type: EXPERIMENTAL
Intervention: Sildenafil added to pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to pirfenidone
Number of subjects: 0
Study: 26938485

Group type: EXPERIMENTAL
Intervention: Representational disengagement
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Linguistic disengagement
Number of subjects: 29
Study: 24684940

Group type: EXPERIMENTAL
Intervention: Continuous oxygen for 72 hours (2 or 3 L/min depending on baseline oxygen saturation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen only (2 or 3 L/min depending on baseline oxygen saturation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No oxygen (control)
Number of subjects: 0
Study: 21744011

Group type: COMPARATOR
Intervention: Creatine (CR; 20 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betaine plus Creatine (BET+CR; 2+20 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betaine (BET; 2 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo (PL)
Number of subjects: 0
Study: 19195772

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study: 17684982

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) in the early postoperative period for preventive purposes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Moistened oxygen insufflation after transition to spontaneous breathing (Control)
Number of subjects: 62
Study: 16167254

Group type: EXPERIMENTAL
Intervention: Immune-enhanced enteral diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular enteral nutrition (EN)
Number of subjects: 72
Study: 11988597

Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Aspirin (75 to 300 mg/d)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: AF patients on no antithrombotic therapy
Number of subjects: 122
Study: 9865219

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study: 7882047

Group type: EXPERIMENTAL
Intervention: Fragrance condition (cologne use)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Race effect
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interaction between race and condition
Number of subjects: 60
Study: 2486442

Group type: EXPERIMENTAL
Intervention: Weight-loss diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiazide-type diuretics
Number of subjects: 0
Study: 6102837

Group type: EXPERIMENTAL
Intervention: Cimetidine, 4 x 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 30998824

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (loading dose 8 mg/kg; maintenance dose 6 mg/kg)
Number of subjects: 596
Study: 28383293

Group type: EXPERIMENTAL
Intervention: General anesthesia plus lumbosacral plexus block with light sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia plus lumbosacral plexus block with deep sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia without lumbosacral plexus block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumbosacral plexus block
Number of subjects: 0
Study: 25827291

Group type: COMPARATOR
Intervention: Weekly cisplatin 40mg/m2 (Arm C)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40mg/m2 and gemcitabine 125mg/m2 (Arm CG)
Number of subjects: 74
Study: 23800333

Group type: EXPERIMENTAL
Intervention: Patient Advocate (PA) intervention for 16 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimal Intervention (MI) control for 16 weeks
Number of subjects: 100
Study: 21540430

Group type: EXPERIMENTAL
Intervention: Prenatal/postpartum lifestyle intervention delivered by telephone
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Prenatal/postpartum lifestyle intervention
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 197
Study: 19886946

Group type: EXPERIMENTAL
Intervention: Color-coded visual scale images (plain image and graded image)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Graded image
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Images
Number of subjects: 261

Group type: COMPARATOR
Intervention: AN lab report
Number of subjects: 261
Study: 17901714

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis
Number of subjects: 397
Study: 15157383

Group type: EXPERIMENTAL
Intervention: Anticholinesterase drugs and steroids treatment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 77

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 77
Study: 11232747

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 3
Study: 15321241

Group type: EXPERIMENTAL
Intervention: Ephedrine bolus (10 mg) and saline infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline bolus and saline infusion (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Saline bolus and two-stage ephedrine infusion (20 mg over 12 min)
Number of subjects: 30
Study: 8161862

Group type: EXPERIMENTAL
Intervention: Cold start of cardiopulmonary bypass (CPB) with prime at room temperature (approximately 20 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic start of CPB with prime warmed up to patients' blood temperature
Number of subjects: 30
Study: 3118711

Group type: EXPERIMENTAL
Intervention: Defatting with acetone prior to catheter insertion and as part of the every-other-day site care regimen
Number of subjects: 100
Study: 31554528

Group type: EXPERIMENTAL
Intervention: Active treatment (nutraceutical mixture including DHA, phosphatidylcholine, silymarin, choline, curcumin, d‐α‐tocopherol)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 113
Study: 29228516

Group type: EXPERIMENTAL
Intervention: Machine learning model using 47 clinical and sociodemographic predictors
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Reduced model with 15 predictors
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Baseline MADRS score, impairment of family, social, and work life, timespan between first and last depressive episode, severity, suicidal risk, age, body mass index, number of lifetime depressive episodes, lifetime duration of hospitalization
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Simplified algorithm of 15 predictors
Number of subjects: 552
Study: 28501100

Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg intravenous)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Direct current synchronized cardioversion (DCC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ibutilide conversion subgroup
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ibutilide nonconversion subgroup
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ibutilide conversion and nonconversion subgroups and DCC group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ibutilide group
Number of subjects: 96

Group type: COMPARATOR
Intervention: DCC group
Number of subjects: 96
Study: 24081558

Group type: EXPERIMENTAL
Intervention: School-based life skills programmes
Number of subjects: 1057
Study: 22366105

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 68
Study: 19697298

Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 54

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 54
Study: 17877952

Group type: EXPERIMENTAL
Intervention: Neoadjuvant antihormonal therapy (tamoxifen and aromatase inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen as primary treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aromatase inhibitors
Number of subjects: 0
Study: 15731395

Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) posture
Number of subjects: 9

Group type: COMPARATOR
Intervention: Supine posture
Number of subjects: 9
Study: 11929056

Group type: EXPERIMENTAL
Intervention: Repellent containing DEET and EBAAP
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 9796605

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.5 MAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC with Nitrous Oxide (N2O)
Number of subjects: 0
Study: 7665538

Group type: EXPERIMENTAL
Intervention: 25 mg/day of clomipramine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg/day of clomipramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clomipramine (both dosages)
Number of subjects: 15
Study: 2719770

Group type: EXPERIMENTAL
Intervention: n-6 essential fatty acid (EFA) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study: 795375

Group type: EXPERIMENTAL
Intervention: Josamycin (2 g daily for 7 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Erythromycin (2 g daily for 7 days)
Number of subjects: 46